Filing Flows › Dogwood Therapeutics (DWTX) › Recalls, complaints & regulation
Dogwood Therapeutics (DWTX): clinical trials
Dogwood Therapeutics (DWTX) beyond its filings: 1 active clinical trial.
Dogwood Therapeutics' latest quarter
Dogwood Therapeutics, Q3 2026: revenue $100K, net loss $4.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Dogwood Therapeutics have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.